DRMA sentiment intelligence

Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW

This article provides the "Price to earnings forward" data for Dermata Therapeutics, Inc. (NASDAQ:DRMAW). It indicates that the market is currently closed, with no trades, and the data is sourced from ICE Data Services and FactSet Research Systems Inc.

Tone

Neutral 50/100

Event

Earnings

Published

19 Jul 2026 06:40

Source

TradingView

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

16 Jul 2026 18:49

Source

Market source

Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW

The article briefly mentions the price to sales forward for Dermata Therapeutics, Inc. (NASDAQ: DRMAW). It is a financial data point presented on the TradingView platform, with no further details or analysis provided within the content itself. The majority of the content consists

Tone

Neutral 50/100

Event

Market update

Published

13 Jul 2026 21:41

Source

TradingView

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 07:00

Source

Market source

Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings

This article provides access to Dermata Therapeutics, Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports from 2021 through 2026. Key updates mentioned include strategic pivots to DTC skincare, clinical trial results for DMT310, and o

Tone

Neutral 50/100

Event

Earnings

Published

04 Jul 2026 12:40

Source

TradingView

Price to earnings forward of Dermata Therapeutics, Inc. – BOATS:DRMAW

This article provides financial information for Dermata Therapeutics, Inc. (DRMAW) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the "Price to earnings forward" metric for the company. The content primarily lists navigation and dat

Tone

Neutral 50/100

Event

Earnings

Published

30 Jun 2026 20:09

Source

TradingView

DRMA Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Dermata Therapeutics, Inc. (DRMA) stock for 2027, according to one analyst. It details the current stock price, market capitalization, volatility, and historical performance, alongside information on earnings, revenue, and emp

Tone

Neutral 50/100

Event

Earnings

Published

28 Jun 2026 15:09

Source

TradingView

Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA

This article provides the "Price to sales forward" value for Dermata Therapeutics, Inc. (NASDAQ: DRMA). It appears to be a financial data snippet from a larger platform, possibly TradingView, indicating a specific financial metric for the company.

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 09:10

Source

TradingView

Enterprise value to EBIT forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA

The article provides a title indicating an analysis of Dermata Therapeutics, Inc.'s enterprise value to EBIT forward. It appears to be a stub or a placeholder page on TradingView, given the lack of actual financial data or detailed content beyond the heading and navigation elemen

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 06:41

Source

TradingView

Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Dermata Therapeutics Inc (DRMAW), covering its support and resistance levels, various technical indicators like MACD and RSI, and moving averages. The analysis indicates a "Sell" signal based on moving averages and a mix of buy and se

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 21:09

Source

TradingKey

Dermata Therapeutics Inc (DRMA) Institutional Confidence

This article provides an overview of Dermata Therapeutics Inc (DRMA)'s institutional confidence, detailing changes in institutional shareholdings. Key shareholders include Proehl (Gerald T), Intracoastal Capital, L.L.C., and Van Hoose (Kyri K), with notable increases in holdings

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 15:40

Source

TradingKey

Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Dermata Therapeutics Inc (DRMA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The current stock price and market capita

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 10:40

Source

TradingKey

Dermata Therapeutics Inc (DRMAW) Institutional Confidence

The article provides an overview of Dermata Therapeutics Inc (DRMAW) with a focus on its institutional confidence

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 09:40

Source

TradingKey

Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Dermata Therapeutics Inc (DRMA), listing major individual and institutional holders and their respective proportions. It also presents a historical overview of institutional shareholding data from Q1 2023 to Q1 2026, showing chang

Tone

Neutral 50/100

Event

Market update

Published

17 Jun 2026 21:11

Source

TradingKey

Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Dermata Therapeutics Inc.'s (DRMA) dividend history and stock split events. It states that the company has not distributed any dividends over the past five years. The article also lists several stock split events, all described as "Merger" typ

Tone

Neutral 50/100

Event

Deals and strategy

Published

17 Jun 2026 21:11

Source

TradingKey

Dermata Therapeutics Inc

This article for Dermata Therapeutics Inc (DRMAW) on TradingKey.com indicates that relevant revenue breakdown data for business segments and regional contributions have not yet been disclosed by the company. It provides basic stock information such as the current price and market

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 05:09

Source

TradingKey

Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Dermata Therapeutics Inc (DRMAW)'s dividend and stock split history, indicating that the company has distributed $0.00 in dividends over the past five years and has no recorded stock splits. It presents current stock performance data, includin

Tone

Neutral 50/100

Event

Capital return

Published

16 Jun 2026 22:09

Source

TradingKey

DRMA - Dermata Therapeutics Inc Stock Price and Quote

This article provides a detailed stock quote and company information for Dermata Therapeutics Inc. (DRMA), including its latest closing price, financial metrics, insider ownership, and recent corporate news. It highlights various financial figures such as market capitalization, i

Tone

Neutral 50/100

Event

Market update

Published

02 Jun 2026 23:40

Source

Finviz

CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D

Dermata Therapeutics, Inc.'s CFO, Kyri Van Hoose, has reported a 9% beneficial ownership stake in the company, totaling 384,352 shares. This significant holding, which includes common shares, warrants, and stock options, largely stems from a private placement in December 2025 whe

Tone

Neutral 50/100

Event

Deals and strategy

Published

01 Jun 2026 20:39

Source

Stock Titan

[EFFECT] Dermata Therapeutics, Inc. SEC Filing

Dermata Therapeutics, Inc. (DRMA) has had an SEC filing of form EFFECT, signaling that a previous S-3 shelf registration statement has become effective. The filing states an effectiveness date of May 29, 2026, and provides details about the company's CIK and file number. The arti

Tone

Neutral 50/100

Event

Market update

Published

01 Jun 2026 10:39

Source

Stock Titan

Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration

Dermata Therapeutics (NASDAQ: DRMA) has filed a $100 million shelf registration for a variety of securities, including common stock, preferred stock, warrants, and debt securities. This filing provides the company with flexibility to raise capital as needed, with specific terms f

Tone

Neutral 50/100

Event

Balance sheet

Published

29 May 2026 21:09

Source

Stock Titan

Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary

Dermata Therapeutics, Inc. filed an 8-K detailing outcomes from its Annual Meeting, notably approving an increase in shares for its 2021 Omnibus Equity Incentive Plan from 153,586 to 402,214, alongside warrant repricing. These approvals, impacting potential dilution and employee

Tone

Neutral 50/100

Event

Market update

Published

28 May 2026 08:39

Source

Minichart